Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...
11h
Fintel on MSNOppenheimer Upgrades Nektar Therapeutics (NKTR)Fintel reports that on March 14, 2025, Oppenheimer upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from ...
Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...
Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...
Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...
2d
Zacks.com on MSNNektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to SayWhile the top- and bottom-line numbers for Nektar (NKTR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare ...
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a ...
Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s ...
Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have earned a consensus rating of “Buy” from the six analysts ...
First, we continue to advance our novel TNFR2 agonist antibody program, NKTR-0165. IND-enabling studies are ongoing with the goal of preparing for an IND submission in the second half of 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results